More frequently than first believed, kidney involvement after SARS-CoV-2 infection is linked to morbidity and mortality. Similar to the etiology of other types of AKI, the pathophysiology of COVID-19 AKI is most likely complex. Although rates of COVID-19 AKI vary significantly across studies and geographical areas, the information currently available points to an incidence of > 20% in hospitalized patients. There are several similarities between COVID-19 AKI and AKI resulting from non-viral causes observed in the ICU, including risk factors, potential processes, and prognosis. Despite noticeably decreased kidney function, acute tubular damage is frequently present, even though it is often minor. Tubular damage most likely results from systemic hemodynamic instability. Despite COVID-19 being referred to as a cytokine storm syndrome, patients with COVID-19 frequently have lower amounts of circulating cytokines than those with acute respiratory distress syndrome from causes other than COVID-19. The prevention and treatment of COVID-19 AKI are poorly understood. Regional'surges in COVID-19 cases might restrict hospital resources, particularly the availability of supplies for dialysis; as a result, thorough daily monitoring of the resources at hand is required. Based on the most recent research, the Acute Disease Quality Initiative recommends diagnosing, preventing, and managing COVID-19 AKI in this Consensus Statement. Additionally, we sought to enhance comprehension of the underlying mechanisms and enhance patient outcomes for COVID-19 AKI. It is essential to comprehend the core molecular mechanisms and the pathophysiology of kidney damage and AKI in COVID19 to create appropriate management plans and therapeutic designs.
| Published in | American Journal of Health Research (Volume 11, Issue 2) |
| DOI | 10.11648/j.ajhr.20231102.12 |
| Page(s) | 40-54 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
SARS-CoV-2, COVID-19, Kidney Injury, Acute Kidney Injury, Kidney Transplant
| [1] | Guan, W.-j., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 2020. 382 (18): p. 1708-1720. |
| [2] | Batlle, D., et al., Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J Am Soc Nephrol, 2020. 31 (7): p. 1380-1383. |
| [3] | Cheng, Y., et al., Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int, 2020. 97 (5): p. 829-838. |
| [4] | Cheng, Y., et al., The Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019. Clin J Am Soc Nephrol, 2020. 15 (10): p. 1394-1402. |
| [5] | Hirsch, J. S., et al., Acute kidney injury in patients hospitalized with COVID-19. Kidney Int, 2020. 98 (1): p. 209-218. |
| [6] | Mohamed, M. M. B., et al., Acute Kidney Injury Associated with Coronavirus Disease 2019 in Urban New Orleans. Kidney360, 2020. 1 (7): p. 614-622. |
| [7] | Cummings, M. J., et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet, 2020. 395 (10239): p. 1763-1770. |
| [8] | Ng, J. H., et al., Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury. Am J Kidney Dis, 2021. 77 (2): p. 204-215. e1. |
| [9] | Nadim, M. K., et al., COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nature Reviews Nephrology, 2020. 16 (12): p. 747-764. |
| [10] | Gupta, S., et al., Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. JAMA Intern Med, 2020. 180 (11): p. 1436-1447. |
| [11] | Murugan, R., et al., Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int, 2010. 77 (6): p. 527-35. |
| [12] | Ahmadian, E., et al., COVID-19 and kidney injury: Pathophysiology and molecular mechanisms. Reviews in medical virology, 2021. 31 (3): p. e2176-e2176. |
| [13] | Khouchlaa, A. and A. Bouyahya, COVID-19 nephropathy: probable mechanisms of kidney failure. J Nephropathol, 2020. 9 (4): p. e35-e35. |
| [14] | Pan, X. W., et al., Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med, 2020. 46 (6): p. 1114-1116. |
| [15] | Diao, B., et al., Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun, 2021. 12 (1): p. 2506. |
| [16] | Malha, L., et al., COVID-19 and the Renin-Angiotensin System. Kidney Int Rep, 2020. 5 (5): p. 563-565. |
| [17] | Tolouian, R., et al., COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Inj Prev, 2020. 9 (2): p. e19-e19. |
| [18] | Ciotti, M., et al., The COVID-19 pandemic. Crit Rev Clin Lab Sci, 2020. 57 (6): p. 365-388. |
| [19] | Andersen, K. G., et al., The proximal origin of SARS-CoV-2. Nat Med, 2020. 26 (4): p. 450-452. |
| [20] | Nao, N., et al., Genetic Predisposition To Acquire a Polybasic Cleavage Site for Highly Pathogenic Avian Influenza Virus Hemagglutinin. mBio, 2017. 8 (1). |
| [21] | Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020. 395 (10223): p. 497-506. |
| [22] | Yuki, K., M. Fujiogi, and S. Koutsogiannaki, COVID-19 pathophysiology: A review. Clin Immunol, 2020. 215: p. 108427. |
| [23] | Shi, H., et al., Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 2020. 20 (4): p. 425-434. |
| [24] | Dhama, K., et al., Coronavirus Disease 2019-COVID-19. Clinical Microbiology Reviews, 2020. 33 (4): p. e00028-20. |
| [25] | Channappanavar, R., J. Zhao, and S. Perlman, T cell-mediated immune response to respiratory coronaviruses. Immunol Res, 2014. 59 (1-3): p. 118-28. |
| [26] | Rabi, F. A., et al., SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens, 2020. 9 (3). |
| [27] | Bosch, B. J., et al., The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol, 2003. 77 (16): p. 8801-11. |
| [28] | Li, W., et al., Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003. 426 (6965): p. 450-4. |
| [29] | Chen, Y., et al., Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun, 2020. 525 (1): p. 135-40. |
| [30] | Walls, A. C., et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020. 181 (2): p. 281-292. e6. |
| [31] | Letko, M., A. Marzi, and V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol, 2020. 5 (4): p. 562-569. |
| [32] | Zou, X., et al., Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med, 2020. 14 (2): p. 185-192. |
| [33] | Drosten, C., et al., Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 2003. 348 (20): p. 1967-76. |
| [34] | Alimohamadi, Y., et al., Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg, 2020. 61 (3): p. E304-e312. |
| [35] | Naicker, S., et al., The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int, 2020. 97 (5): p. 824-828. |
| [36] | Dadson, P., et al., Underlying Kidney Diseases and Complications for COVID-19: A Review. Front Med (Lausanne), 2020. 7: p. 600144. |
| [37] | Yang, X., et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020. 8 (5): p. 475-481. |
| [38] | Anderson, R. M., et al., How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet, 2020. 395 (10228): p. 931-934. |
| [39] | Guo, Y. R., et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 2020. 7 (1): p. 11. |
| [40] | Yu, N., et al., Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis, 2020. 20 (5): p. 559-564. |
| [41] | Zheng, X., Y. Zhao, and L. Yang, Acute Kidney Injury in COVID-19: The Chinese Experience. Semin Nephrol, 2020. 40 (5): p. 430-442. |
| [42] | Chong, W. H. and B. K. Saha, Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). Am J Med Sci, 2021. 361 (3): p. 287-296. |
| [43] | Smarz-Widelska, I., et al., Pathophysiology and Clinical Manifestations of COVID-19-Related Acute Kidney Injury-The Current State of Knowledge and Future Perspectives. Int J Mol Sci, 2021. 22 (13). |
| [44] | Bonventre, J. V. and L. Yang, Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest, 2011. 121 (11): p. 4210-21. |
| [45] | Legrand, M., et al., Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol, 2021. 17 (11): p. 751-764. |
| [46] | Ng, J. H., et al., Pathophysiology and pathology of acute kidney injury in patients with COVID-19. Advances in Chronic Kidney Disease, 2020. 27 (5): p. 365-376. |
| [47] | Xia, P., et al., Clinicopathological features and outcomes of acute kidney injury in critically ill COVID-19 with prolonged disease course: a retrospective cohort. Journal of the American Society of Nephrology, 2020. 31 (9): p. 2205-2221. |
| [48] | Santoriello, D., et al., Postmortem kidney pathology findings in patients with COVID-19. Journal of the American Society of Nephrology, 2020. 31 (9): p. 2158-2167. |
| [49] | Sharma, P., et al., COVID-19–associated kidney injury: a case series of kidney biopsy findings. Journal of the American Society of Nephrology, 2020. 31 (9): p. 1948-1958. |
| [50] | Ferlicot, S., et al., The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. Nephrology Dialysis Transplantation, 2021. 36 (7): p. 1253-1262. |
| [51] | Hanif MO, B. A., Ramphul K, Acute Renal Tubular Necrosis. StatPearls 2022 Jan. |
| [52] | Karakala, N. and A. J. Tolwani, Timing of renal replacement therapy for acute kidney injury. Journal of Intensive Care Medicine, 2019. 34 (2): p. 94-103. |
| [53] | Ye, Q., B. Wang, and J. Mao, The pathogenesis and treatment of theCytokine Storm'in COVID-19. Journal of infection, 2020. 80 (6): p. 607-613. |
| [54] | Larsen, C. P., et al., Collapsing glomerulopathy in a patient with COVID-19. Kidney international reports, 2020. 5 (6): p. 935. |
| [55] | Nasr, S. H. and J. B. Kopp, COVID-19–associated collapsing glomerulopathy: an emerging entity. Kidney international reports, 2020. 5 (6): p. 759. |
| [56] | D'Agati, V. D., F. J. Kaskel, and R. J. Falk, Focal segmental glomerulosclerosis. New England Journal of Medicine, 2011. 365 (25): p. 2398-2411. |
| [57] | Velez, J. C. Q., T. Caza, and C. P. Larsen, COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nature Reviews Nephrology, 2020. 16 (10): p. 565-567. |
| [58] | Delsante, M., et al., Kidney Involvement in COVID-19: Need for Better Definitions. J Am Soc Nephrol, 2020. 31 (9): p. 2224-2225. |
| [59] | Jain, U., Effect of COVID-19 on the Organs. Cureus, 2020. 12 (8): p. e9540. |
| [60] | Han, X. and Q. Ye, Kidney involvement in COVID-19 and its treatments. J Med Virol, 2021. 93 (3): p. 1387-1395. |
| [61] | Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020. 395 (10223): p. 507-513. |
| [62] | Richardson, S., et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama, 2020. 323 (20): p. 2052-2059. |
| [63] | Wang, D., et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama, 2020. 323 (11): p. 1061-1069. |
| [64] | Guzik, T. J., et al., COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res, 2020. 116 (10): p. 1666-1687. |
| [65] | Wang, L., et al., Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol, 2020. 51 (5): p. 343-348. |
| [66] | Gabarre, P., et al., Acute kidney injury in critically ill patients with COVID-19. Intensive Care Medicine, 2020. 46 (7): p. 1339-1348. |
| [67] | Laghlam, D., M. Jozwiak, and L. S. Nguyen, Renin-Angiotensin-Aldosterone System and Immunomodulation: A State-of-the-Art Review. Cells, 2021. 10 (7). |
| [68] | Schneider, W. M., et al., Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks. Cell, 2021. 184 (1): p. 120-132. e14. |
| [69] | Deshotels, M. R., et al., Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension, 2014. 64 (6): p. 1368-1375. |
| [70] | Zhou, F., et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020. 395 (10229): p. 1054-1062. |
| [71] | Su, H., C. T. Lei, and C. Zhang, Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. Front Immunol, 2017. 8: p. 405. |
| [72] | Valizadeh, R., et al., Coronavirus-nephropathy; renal involvement in COVID-19. J Renal Inj Prev, 2020. 9 (2): p. e18. |
| [73] | Kapp, M. E., et al., Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. Asaio Journal, 2021. 67 (10): p. 1087. |
| [74] | Khan, S., et al., Does SARS-CoV-2 infect the kidney? Journal of the American Society of Nephrology, 2020. 31 (12): p. 2746-2748. |
| [75] | Fogagnolo, A., et al., Focus on renal blood flow in mechanically ventilated patients with SARS-CoV-2: a prospective pilot study. J Clin Monit Comput, 2022. 36 (1): p. 161-167. |
| [76] | Vasquez-Bonilla, W. O., et al., A review of the main histopathological findings in coronavirus disease 2019. Hum Pathol, 2020. 105: p. 74-83. |
| [77] | Bowe, B., et al., Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clin J Am Soc Nephrol, 2020. 16 (1): p. 14-25. |
| [78] | Legrand, M., et al., When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome. Crit Care Med, 2014. 42 (9): p. 2109-17. |
| [79] | Kawakami, R., et al., Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol, 2021. 77 (3): p. 314-325. |
| [80] | Grasselli, G., et al., Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. Jama, 2020. 323 (16): p. 1574-1581. |
| [81] | Guan, W. J. and N. S. Zhong, Clinical Characteristics of COVID-19 in China. Reply. N Engl J Med, 2020. 382 (19): p. 1861-1862. |
| [82] | Panitchote, A., et al., Factors associated with acute kidney injury in acute respiratory distress syndrome. Annals of Intensive Care, 2019. 9 (1): p. 74. |
| [83] | Zimmerman, J. E., et al., Intensive care unit length of stay: Benchmarking based on Acute Physiology and Chronic Health Evaluation (APACHE) IV. Crit Care Med, 2006. 34 (10): p. 2517-29. |
| [84] | El Mouhayyar, C., et al., Factors Associated with Severity of Acute Kidney Injury and Adverse Outcomes in Critically Ill Patients with COVID-19. Nephron, 2022: p. 1-9. |
| [85] | Levy, J. H., T. Iba, and E. E. Gardiner, Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. Arterioscler Thromb Vasc Biol, 2021. 41 (5): p. 1774-1776. |
| [86] | Rossi, G. M., et al., Kidney Biopsy Findings in a Critically Ill COVID-19 Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against "SARS-CoV-2 Nephropathy". Kidney Int Rep, 2020. 5 (7): p. 1100-1105. |
| [87] | Szajek, K., et al., Granulomatous interstitial nephritis in a patient with SARS-CoV-2 infection. BMC Nephrol, 2021. 22 (1): p. 19. |
| [88] | Ostermann, M., et al., Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA network open, 2020. 3 (10): p. e2019209-e2019209. |
| [89] | Werion, A., et al., SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney international, 2020. 98 (5): p. 1296-1307. |
| [90] | Gansevoort, R. T., et al., Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet, 2013. 382 (9889): p. 339-352. |
| [91] | Su, H., et al., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international, 2020. 98 (1): p. 219-227. |
| [92] | Zahid, U., et al., Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications. American journal of nephrology, 2020. 51 (10): p. 786-796. |
| [93] | Lazzaroni, M. G., et al., Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood reviews, 2021. 46: p. 100745. |
| [94] | Goeijenbier, M., et al., Viral infections and mechanisms of thrombosis and bleeding. Journal of medical virology, 2012. 84 (10): p. 1680-1696. |
| [95] | Pei, G., et al., Renal involvement and early prognosis in patients with COVID-19 pneumonia. Journal of the American Society of Nephrology, 2020. 31 (6): p. 1157-1165. |
| [96] | Mehta, P., et al., COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet, 2020. 395 (10229): p. 1033-1034. |
| [97] | Xu, X., et al., Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences, 2020. 117 (20): p. 10970-10975. |
| [98] | Levi, M. and T. van der Poll, Coagulation and sepsis. Thrombosis research, 2017. 149: p. 38-44. |
| [99] | Stirling, D., W. A. Hannant, and C. A. Ludlam, Transcriptional activation of the factor VIII gene in liver cell lines by interleukin-6. Thrombosis and haemostasis, 1998. 59 (01): p. 74-78. |
| [100] | Stouthard, J. M., et al., Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thrombosis and haemostasis, 1996. 76 (11): p. 738-742. |
| [101] | Cohen, T., Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin. 6: p. 736-741. |
| [102] | Desai, T. R., et al., Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. Journal of surgical research, 2002. 104 (2): p. 118-123. |
| [103] | Henderson, L. A., et al., On the alert for cytokine storm: immunopathology in COVID-19. Arthritis & rheumatology, 2020. 72 (7): p. 1059-1063. |
| [104] | Zunke, F. and S. Rose-John, The shedding protease ADAM17: Physiology and pathophysiology. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2017. 1864 (11): p. 2059-2070. |
| [105] | Qu, R., et al., Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. Journal of medical virology, 2020. 92 (9): p. 1533-1541. |
| [106] | Mangalmurti, N. and C. A. Hunter, Cytokine storms: understanding COVID-19. Immunity, 2020. 53 (1): p. 19-25. |
| [107] | Askari, H., et al., Kidney diseases and COVID-19 infection: causes and effect, supportive therapeutics and nutritional perspectives. Heliyon, 2021. 7 (1): p. e06008. |
| [108] | Qin, C., et al., Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis, 2020. 71 (15): p. 762-768. |
| [109] | He, W., et al., Mechanisms of SARS-CoV-2 Infection-Induced Kidney Injury: A Literature Review. Front Cell Infect Microbiol, 2022. 12: p. 838213. |
| [110] | Chen, D., et al., Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19). medRxiv, 2020: p. 2020.02.27.20028530. |
| [111] | Tan, L., et al., Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther, 2020. 5 (1): p. 33. |
| [112] | Winkler, A., et al., SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report. BMC Nephrol, 2021. 22 (1): p. 75. |
| [113] | Macor, P., et al., Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. Biomedicines, 2021. 9 (8). |
| [114] | Jedlowski, P. M. and M. F. Jedlowski, Coronavirus disease 2019-associated immunoglobulin A vasculitis/Henoch-Schönlein purpura: A case report and review. J Dermatol, 2022. 49 (1): p. 190-196. |
| [115] | Noris, M., A. Benigni, and G. Remuzzi, The case of complement activation in COVID-19 multiorgan impact. Kidney Int, 2020. 98 (2): p. 314-322. |
| [116] | David, S., et al., Alternative pathway complement activation induces proinflammatory activity in human proximal tubular epithelial cells. Nephrol Dial Transplant, 1997. 12 (1): p. 51-6. |
| [117] | Cybulsky, A. V., et al., Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem, 2002. 277 (44): p. 41342-51. |
| [118] | He, Z., et al., Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis, 2005. 9 (6): p. 323-30. |
| [119] | Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020. 181 (2): p. 271-280. e8. |
| [120] | Karnik, S. S., et al., International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol Rev, 2015. 67 (4): p. 754-819. |
| [121] | Williams, B., et al., Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension, 1995. 25 (5): p. 913-7. |
| [122] | Fyhrquist, F. and O. Saijonmaa, Renin-angiotensin system revisited. J Intern Med, 2008. 264 (3): p. 224-36. |
| [123] | Nataraj, C., et al., Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest, 1999. 104 (12): p. 1693-701. |
| [124] | Langenberg, C., et al., Renal blood flow and function during recovery from experimental septic acute kidney injury. Intensive Care Med, 2007. 33 (9): p. 1614-8. |
| [125] | Joannidis, M., et al., Neutrophil transmigration in renal proximal tubular LLC-PK1 cells. Cell Physiol Biochem, 2004. 14 (1-2): p. 101-12. |
| [126] | Bellomo, R., et al., Acute kidney injury in sepsis. Intensive Care Med, 2017. 43 (6): p. 816-828. |
| [127] | Lerolle, N., et al., Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med, 2010. 36 (3): p. 471-8. |
| [128] | Bernardo, A., et al., Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood, 2004. 104 (1): p. 100-6. |
| [129] | Delvaeye, M. and E. M. Conway, Coagulation and innate immune responses: can we view them separately? Blood, 2009. 114 (12): p. 2367-74. |
| [130] | Darmon, M., et al., Impact of mild hypoxemia on renal function and renal resistive index during mechanical ventilation. Intensive Care Med, 2009. 35 (6): p. 1031-8. |
| [131] | Legrand, M., et al., Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care, 2013. 17 (6): p. R278. |
| [132] | Xiao, Z., et al., Emerging early diagnostic methods for acute kidney injury. Theranostics, 2022. 12 (6): p. 2963-2986. |
| [133] | Wen, Y. and C. R. Parikh, The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression. J Am Soc Nephrol, 2021. 32 (1): p. 2-4. |
| [134] | Ronco, C., R. Bellomo, and J. A. Kellum, Acute kidney injury. The Lancet, 2019. 394 (10212): p. 1949-1964. |
| [135] | Vogel, M. J., et al., Kidney injury molecule-1: potential biomarker of acute kidney injury and disease severity in patients with COVID-19. Journal of Nephrology, 2021. 34 (4): p. 1007-1018. |
| [136] | Burwick, R. M., et al., Differentiating Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome and Atypical Hemolytic Uremic Syndrome in the Postpartum Period. Hypertension, 2021. 78 (3): p. 760-768. |
| [137] | Moresco, R. N., et al., Urinary kidney injury molecule-1 in renal disease. Clinica chimica acta, 2018. 487: p. 15-21. |
| [138] | Cheng, P., et al., Multiplex Optical Urinalysis for Early Detection of Drug-Induced Kidney Injury. Anal Chem, 2020. 92 (8): p. 6166-6172. |
| [139] | Lim, J. H., et al., Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury. J Clin Med, 2020. 9 (6). |
| [140] | Farkash, E. A., A. M. Wilson, and J. M. Jentzen, Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. J Am Soc Nephrol, 2020. 31 (8): p. 1683-1687. |
| [141] | Gu, Y. Y., et al., Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study. PLoS One, 2021. 16 (1): p. e0245209. |
| [142] | Huang, Y. F., et al., Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol Res, 2020. 158: p. 104939. |
| [143] | Abian, O., et al., Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol, 2020. 164: p. 1693-1703. |
| [144] | Williamson, G. and A. Kerimi, Testing of natural products in clinical trials targeting the SARS-CoV-2 (COVID-19) viral spike protein-angiotensin converting enzyme-2 (ACE2) interaction. Biochem Pharmacol, 2020. 178: p. 114123. |
| [145] | Vijayakumar, B. G., et al., In silico pharmacokinetic and molecular docking studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. Eur J Pharmacol, 2020. 886: p. 173448. |
| [146] | Rudd, K. E., et al., Pragmatic Recommendations for the Prevention and Treatment of Acute Kidney Injury in Patients with COVID-19 in Low- and Middle-Income Countries. Am J Trop Med Hyg, 2021. 104 (3_Suppl): p. 87-98. |
| [147] | Puelles, V. G., et al., Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med, 2020. 383 (6): p. 590-592. |
| [148] | Soleimani, M., Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells. Int J Mol Sci, 2020. 21 (9). |
| [149] | Ronco, C., T. Reis, and F. Husain-Syed, Management of acute kidney injury in patients with COVID-19. Lancet Respir Med, 2020. 8 (7): p. 738-742. |
| [150] | Hassanein, M., G. Thomas, and J. Taliercio, Management of acute kidney injury in COVID-19. Cleveland Clinic Journal of Medicine, 2020. |
| [151] | Diebold, M., et al., Acute kidney injury in patients with COVID-19: a retrospective cohort study from Switzerland. Swiss Med Wkly, 2021. 151: p. w20482. |
| [152] | Kim, S. Y. and A. Moon, Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul), 2012. 20 (3): p. 268-72. |
| [153] | Gounden, V., H. Bhatt, and I. Jialal, Renal Function Tests, in StatPearls. 2022, StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.: Treasure Island (FL). |
| [154] | Neves, P., et al., Acute Kidney Injury Due to COVID-19 in Intensive Care Unit: An Analysis From a Latin-American Center. Front Med (Lausanne), 2021. 8: p. 620050. |
| [155] | Wishahi, M. and N. M. Kamal, Multidisciplinary basic and clinical research of acute kidney injury with COVID-19: Pathophysiology, mechanisms, incidence, management and kidney transplantation. World J Nephrol, 2022. 11 (3): p. 105-114. |
| [156] | Lobo, V. A., Renal Replacement Therapy in Acute Kidney Injury: Which Mode and When? Indian J Crit Care Med, 2020. 24 (Suppl 3): p. S102-s106. |
| [157] | Joannidis, M., et al., Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med, 2020. 46 (4): p. 654-672. |
| [158] | Husain-Syed, F., et al., Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk. Intensive Care Med, 2018. 44 (9): p. 1447-1459. |
| [159] | Dennis, J. M. and P. K. Witting, Protective role for antioxidants in acute kidney disease. Nutrients, 2017. 9 (7): p. 718. |
| [160] | Katoh, H., et al., RenalGuard system to prevent contrast-induced acute kidney injury in Japanese patients with renal dysfunction; RESPECT KIDNEY study. Cardiovascular intervention and therapeutics, 2019. 34 (2): p. 105-112. |
| [161] | Ostermann, M., K. Liu, and K. Kashani, Fluid management in acute kidney injury. Chest, 2019. 156 (3): p. 594-603. |
| [162] | Al-Jaghbeer, M., et al., Clinical decision support for in-hospital AKI. Journal of the American Society of Nephrology, 2018. 29 (2): p. 654-660. |
| [163] | Ostermann, M. and M. Joannidis, Acute kidney injury 2016: diagnosis and diagnostic workup. Critical care, 2016. 20 (1): p. 1-13. |
| [164] | Annigeri, R. A., et al., Renal support for acute kidney injury in the developing world. Kidney International Reports, 2017. 2 (4): p. 559-578. |
| [165] | Qian, J., et al., Early Renal-Replacement Therapy May Reduce the All-Cause Mortality of Severe COVID-19: An Observational Cohort Study. Blood Purif, 2022: p. 1-9. |
| [166] | Kellum, J. A., et al., Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney international supplements, 2012. 2 (1): p. 1-138. |
| [167] | Raina, R., et al., Kidney replacement therapy in COVID-19 induced kidney failure and septic shock: a pediatric continuous renal replacement therapy [PCRRT] position on emergency preparedness with resource allocation. Frontiers in pediatrics, 2020. 8: p. 413. |
| [168] | Yang, Y., et al., Effect of continuous renal replacement therapy on all-cause mortality in COVID-19 patients undergoing invasive mechanical ventilation: a retrospective cohort study. MedRxiv, 2020. |
| [169] | Palmisano, A., et al., Acute Kidney Injury (AKI) before and after Kidney Transplantation: Causes, Medical Approach, and Implications for the Long-Term Outcomes. J Clin Med, 2021. 10 (7). |
| [170] | Cukuranovic, J., et al., Viral infection in renal transplant recipients. ScientificWorldJournal, 2012. 2012: p. 820621. |
| [171] | Lubetzky, M., et al., Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. Nephrol Dial Transplant, 2020. 35 (7): p. 1250-1261. |
| [172] | Nair, V., et al., COVID-19 in kidney transplant recipients. Am J Transplant, 2020. 20 (7): p. 1819-1825. |
| [173] | Zhang, H., et al., Identification of Kidney Transplant Recipients with Coronavirus Disease 2019. Eur Urol, 2020. 77 (6): p. 742-747. |
| [174] | Alberici, F., et al., Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep, 2020. 5 (5): p. 580-585. |
APA Style
Md. Aminul Islam Apu, Aar Rafi Mahmud, Md. Rifat Sarker, Dibyendu Halder, Nova Rahman, et al. (2023). COVID-19: Associated Acute Kidney Injury (AKI) Pathology and Therapies from Complementary and Alternative Medicine. American Journal of Health Research, 11(2), 40-54. https://doi.org/10.11648/j.ajhr.20231102.12
ACS Style
Md. Aminul Islam Apu; Aar Rafi Mahmud; Md. Rifat Sarker; Dibyendu Halder; Nova Rahman, et al. COVID-19: Associated Acute Kidney Injury (AKI) Pathology and Therapies from Complementary and Alternative Medicine. Am. J. Health Res. 2023, 11(2), 40-54. doi: 10.11648/j.ajhr.20231102.12
AMA Style
Md. Aminul Islam Apu, Aar Rafi Mahmud, Md. Rifat Sarker, Dibyendu Halder, Nova Rahman, et al. COVID-19: Associated Acute Kidney Injury (AKI) Pathology and Therapies from Complementary and Alternative Medicine. Am J Health Res. 2023;11(2):40-54. doi: 10.11648/j.ajhr.20231102.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajhr.20231102.12,
author = {Md. Aminul Islam Apu and Aar Rafi Mahmud and Md. Rifat Sarker and Dibyendu Halder and Nova Rahman and Md. Shahporan Shuvo and Raihana Akter Nira},
title = {COVID-19: Associated Acute Kidney Injury (AKI) Pathology and Therapies from Complementary and Alternative Medicine},
journal = {American Journal of Health Research},
volume = {11},
number = {2},
pages = {40-54},
doi = {10.11648/j.ajhr.20231102.12},
url = {https://doi.org/10.11648/j.ajhr.20231102.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20231102.12},
abstract = {More frequently than first believed, kidney involvement after SARS-CoV-2 infection is linked to morbidity and mortality. Similar to the etiology of other types of AKI, the pathophysiology of COVID-19 AKI is most likely complex. Although rates of COVID-19 AKI vary significantly across studies and geographical areas, the information currently available points to an incidence of > 20% in hospitalized patients. There are several similarities between COVID-19 AKI and AKI resulting from non-viral causes observed in the ICU, including risk factors, potential processes, and prognosis. Despite noticeably decreased kidney function, acute tubular damage is frequently present, even though it is often minor. Tubular damage most likely results from systemic hemodynamic instability. Despite COVID-19 being referred to as a cytokine storm syndrome, patients with COVID-19 frequently have lower amounts of circulating cytokines than those with acute respiratory distress syndrome from causes other than COVID-19. The prevention and treatment of COVID-19 AKI are poorly understood. Regional'surges in COVID-19 cases might restrict hospital resources, particularly the availability of supplies for dialysis; as a result, thorough daily monitoring of the resources at hand is required. Based on the most recent research, the Acute Disease Quality Initiative recommends diagnosing, preventing, and managing COVID-19 AKI in this Consensus Statement. Additionally, we sought to enhance comprehension of the underlying mechanisms and enhance patient outcomes for COVID-19 AKI. It is essential to comprehend the core molecular mechanisms and the pathophysiology of kidney damage and AKI in COVID19 to create appropriate management plans and therapeutic designs.},
year = {2023}
}
TY - JOUR T1 - COVID-19: Associated Acute Kidney Injury (AKI) Pathology and Therapies from Complementary and Alternative Medicine AU - Md. Aminul Islam Apu AU - Aar Rafi Mahmud AU - Md. Rifat Sarker AU - Dibyendu Halder AU - Nova Rahman AU - Md. Shahporan Shuvo AU - Raihana Akter Nira Y1 - 2023/04/11 PY - 2023 N1 - https://doi.org/10.11648/j.ajhr.20231102.12 DO - 10.11648/j.ajhr.20231102.12 T2 - American Journal of Health Research JF - American Journal of Health Research JO - American Journal of Health Research SP - 40 EP - 54 PB - Science Publishing Group SN - 2330-8796 UR - https://doi.org/10.11648/j.ajhr.20231102.12 AB - More frequently than first believed, kidney involvement after SARS-CoV-2 infection is linked to morbidity and mortality. Similar to the etiology of other types of AKI, the pathophysiology of COVID-19 AKI is most likely complex. Although rates of COVID-19 AKI vary significantly across studies and geographical areas, the information currently available points to an incidence of > 20% in hospitalized patients. There are several similarities between COVID-19 AKI and AKI resulting from non-viral causes observed in the ICU, including risk factors, potential processes, and prognosis. Despite noticeably decreased kidney function, acute tubular damage is frequently present, even though it is often minor. Tubular damage most likely results from systemic hemodynamic instability. Despite COVID-19 being referred to as a cytokine storm syndrome, patients with COVID-19 frequently have lower amounts of circulating cytokines than those with acute respiratory distress syndrome from causes other than COVID-19. The prevention and treatment of COVID-19 AKI are poorly understood. Regional'surges in COVID-19 cases might restrict hospital resources, particularly the availability of supplies for dialysis; as a result, thorough daily monitoring of the resources at hand is required. Based on the most recent research, the Acute Disease Quality Initiative recommends diagnosing, preventing, and managing COVID-19 AKI in this Consensus Statement. Additionally, we sought to enhance comprehension of the underlying mechanisms and enhance patient outcomes for COVID-19 AKI. It is essential to comprehend the core molecular mechanisms and the pathophysiology of kidney damage and AKI in COVID19 to create appropriate management plans and therapeutic designs. VL - 11 IS - 2 ER -
Email: